AbbVie Inc. (ABBV)

ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.

AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.

High yield can sometimes lead to high turnover. Income investors may need to be prepared to sell high-yield dividend stocks quickly if their dividends appear to be at risk.

AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

AbbVie (ABBV 0.98%) became a stand-alone, publicly traded company when it split from its former parent, Abbott Laboratories, in 2013. The reason for the split was for each company to generate greater ...

Inflation isn't soaring as much as expected. More interest rate cuts could be on the way from the Federal Reserve.

July saw strong market gains, especially in tech, but finding bargains is tough as indices approach all-time highs. I focused July investments on high-yield BDCs like OBDC, MFIC, and BXSL, maintaining...

AbbVie Inc.'s Q2 2025 results highlight Skyrizi and Rinvoq's dominance, replacing Humira and driving impressive revenue growth, with both drugs exceeding expectations. The company's aggressive neurosc...

Short-term market fluctuations can be stressful, there's no doubt about that. The good news is, long-term investors are in a better position to weather these storms.